#United States #New York #Securities Fraud #Wolf Haldenstein #Replimune Group

Attention Replimune Investors: Join the Class Action Now

Investors who purchased shares of Replimune Group, Inc. (NASDAQ: REPL) during the specified class period from November 22, 2024, to July 21, 2025, have an urgent opportunity to take action regarding their financial losses. A class action lawsuit was recently filed against the company, pursuing claims of possible securities fraud and other unlawful business practices linked to the firm’s executives. This lawsuit has been initiated by Wolf Haldenstein Adler Freeman & Herz LLP, a prominent law firm specializing in investor rights and securities litigation.

Class Action Background

The core of the allegations revolves around Replimune's submission of its Biologics License Application (BLA) for RP1, a treatment intended for advanced melanoma. On July 22, 2025, the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL), decisively rejecting this application. The FDA concluded that the clinical trial findings did not substantiate the product's effectiveness convincingly. Furthermore, the study’s design reportedly needs significant revisions due to issues with patient variability, although no safety concerns were reported.

Following the FDA’s pronouncement, Replimune's share value plummeted—a staggering drop of 77.24%, translating to a loss of $9.52 per share, which closed at just $2.81 that day. This drastic decline in stock price sent ripples across the investment community, prompting many investors to question the information conveyed by the company prior to this revelation.

Important Deadline

The window for shareholders to act is narrowing. Investors are encouraged to contact Wolf Haldenstein immediately to explore their options for becoming lead plaintiffs in this class action suit. The firm's dedicated legal team advises that plaintiffs must take steps before the upcoming deadline of September 22, 2025, to assert their rights. Being appointed as a lead plaintiff can significantly amplify the voice of investors within the proceedings.

Why Choose Wolf Haldenstein?

Founded in 1888, Wolf Haldenstein is well-respected for its commitment to protecting investor rights and advocating for justice in the face of financial wrongdoing. With over 125 years of legal expertise, they have a robust history of success in securities cases. The firm provides a transparent and diligent approach to each case, firmly standing by their clients who have suffered due to misrepresentations in the financial market.

Contact Information

Investors affected by this situation or those who have pertinent information about Replimune's business practices are urged to reach out to the law firm:

• - Phone: (800) 575-0735 or (212) 545-4774
• - Email: [email protected]
• - Contact Person: Gregory Stone, Director of Case and Financial Analysis
• - Website: Wolf Haldenstein Adler Freeman & Herz LLP

In light of the circumstances surrounding Replimune, investor participation is critical. Your voice can help hold the responsible parties accountable for their actions, ensuring that those affected can seek restitution for their losses. Don’t hesitate—contact the firm today to determine your eligibility in joining this important class action lawsuit.